<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04770142</url>
  </required_header>
  <id_info>
    <org_study_id>TIRA-FIM</org_study_id>
    <nct_id>NCT04770142</nct_id>
  </id_info>
  <brief_title>First-in-Man Early Feasibility Study for Transcatheter HOCM Septal Ablation</brief_title>
  <official_title>The Study for Evaluation of Safety and Efficacy of Transcatheter RF Ablation System (TIRA Catheter) to Treat Hypertrophic Obstructive Cardiomyopathy : Multi-center, Open Label, Single Arm, Investigator Initiated Exploratory Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tau Pnu Medical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tau Pnu Medical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Transcatheter Intra-septal RF ablation system (TIRA catheter with its supplemental devices)&#xD;
      to treat hypertrophic obstructive cardiomyopathy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this multi-center, open label, single arm, investigator initiated&#xD;
      exploratory pilot study is to evaluation of safety and efficacy of transcatheter Intra-septal&#xD;
      RF ablation system (TIRA catheter with its supplemental devices), in treating hypertrophic&#xD;
      obstructive cardiomyopathy(HOCM).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 20, 2021</start_date>
  <completion_date type="Anticipated">August 7, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 20, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>multi-center, open label, single arm, investigator initiated exploratory pilot study</intervention_model_description>
    <primary_purpose>Device Feasibility</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of LVOT obstruction</measure>
    <time_frame>immediately after the procedure and 1 month</time_frame>
    <description>LVOT gradient (mmHg) ; resting / valsalva maneuver with Echocardiogram</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of LVOT and Septum(1)</measure>
    <time_frame>immediately after the procedure and 1 month</time_frame>
    <description>LVOT diameter (mm) with Echocardiogram</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of LVOT and Septum(2)</measure>
    <time_frame>immediately after the procedure and 1 month</time_frame>
    <description>Intraventricular septum(IVS) thickness (mm) with Echocardiogram</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Morphological Structural Changes in the Lesion Area</measure>
    <time_frame>immediately after the procedure and 1 month</time_frame>
    <description>Intraventricular septum(IVS) thickness (mm) with cardiac CT and MRI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of adverse events as a measure of safety</measure>
    <time_frame>immediately after the procedure and 1 month</time_frame>
    <description>Rate of composite endpoint of MACE *death, myocardial infarction, cardiac tamponade, device related acrdiac surgery, stroke</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of LVOT obstruction</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>LVOT gradient (mmHg) ; resting / valsalva maneuver with Echocardiogram</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of LVOT and Septum(1)</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>LVOT diameter (mm) with Echocardiogram</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of LVOT and Septum(2)</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Intraventricular septum(IVS) thickness (mm) with Echocardiogram</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of LVOT and Septum(3)</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Left atrial volume index (ml/m2) with Echocardiogram</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of LVOT and Septum(4)</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Mitral regurgitation volume (ml) with Echocardiogram</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of LVOT and Septum(5)</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Systolic anterior motion of the mitral valve (SAM) with Echocardiogram</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morphological Structural Changes in the Lesion Area</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Intraventricular septum(IVS) thickness (mm) with cardiac CT and MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of adverse events as a measure of safety</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Rate of composite endpoint of MACE *death, myocardial infarction, cardiac tamponade, device related acrdiac surgery, stroke</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">7</enrollment>
  <condition>Hypertrophic Obstructive Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>TIRA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>treated with transcatheter RF ablation system (TIRA catheter with its supplemental devices)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TIRA catheter</intervention_name>
    <description>treat hypertrophic obstructive cardiomyopathy</description>
    <arm_group_label>TIRA</arm_group_label>
    <other_name>CA10 and ohter 3 models</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  NYHA(New York Heart Association) Class Ⅱ to Ⅳ in spite of optimal medical treatment.&#xD;
             (For optimal medical treatment, β-blocker or diuretic such as calcium antagonists&#xD;
             should be given for at least 3 months.)&#xD;
&#xD;
          -  Patients with left ventricular effusion gradient (LVOT) greater than (1) 30 mmHg at&#xD;
             rest or (2) at least 50 mmHg at physiological exercise/dobutamine&#xD;
             administration/balsalva manuver. (The pressure difference due to the left ventricle&#xD;
             drain must be the proximal mitral valve-septal contact by the systolic motion of&#xD;
             mitral valve (SAM).)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Target area wall thickness ≤15mm&#xD;
&#xD;
          -  LV ejection fraction ≤30%&#xD;
&#xD;
          -  Subjects who have unsuitable septal vein and coronary sinus anatomy by cardiac CT or&#xD;
             venogram&#xD;
&#xD;
          -  Conduction disturbance; LBBB or RBBB&#xD;
&#xD;
          -  Advanced AV block without permanent pacemaker&#xD;
&#xD;
          -  Subjects who have experience in performing vascular stent procedures (PCI) or CABG on&#xD;
             coronary arteries close to the coronary sinus within 3 months.&#xD;
&#xD;
          -  Severe pulmonary HTN ≥70mmHg&#xD;
&#xD;
          -  Subjects who have cardiogenic shock and those who have an expected life expectancy of&#xD;
             12 months or less.&#xD;
&#xD;
          -  Subjects with other valve diseases (companion disease) that require surgical treatment&#xD;
             (in this case, Systolic motion of the mitral valve (SAM) caused by systolic myocardia&#xD;
             is not considered a companion disease).&#xD;
&#xD;
          -  Subjects who are pregnant, or lactating, or plan pregnacy during the clinical trials&#xD;
&#xD;
          -  Subjects who are participated in other clinical trials within 1 month of enrollment&#xD;
&#xD;
          -  Subjects who are deemed not to be eligible in this study by physician's discretion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seung-Whan Lee, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Seung-Whan Lee, MD, PhD</last_name>
    <phone>+82553678783</phone>
    <email>seungwlee@amc.seoul.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>June-Hong Kim, MD, PhD</last_name>
    <phone>+82553678783</phone>
    <email>junehongk@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chungnam National University Sejong Hospital</name>
      <address>
        <city>Sejong</city>
        <state>Bodeum7ro</state>
        <zip>30099</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jae-Hwan Lee, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Jae-Hwan Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Keimyung University Dongsan Hospital</name>
      <address>
        <city>Daegu</city>
        <state>Dalseo-gu</state>
        <zip>42601</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cheol-Hyun Lee</last_name>
      <phone>+82-53-250-7314</phone>
    </contact>
    <investigator>
      <last_name>Cheol-Hyun Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>In-Chul Kim</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hallym University Medical Center</name>
      <address>
        <city>Anyang</city>
        <state>Dongan-gu</state>
        <zip>14068</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hyun-Suk Kim, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Hyun-Suk Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Youn-suck Koh</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sejong HOSPITAL</name>
      <address>
        <city>Bucheon-si</city>
        <state>Gyeonggi-do</state>
        <zip>14754</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Young-Jin Choi</last_name>
      <phone>+82-1599-6677</phone>
    </contact>
    <investigator>
      <last_name>Young-Jin Choi</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ha-Uk Park</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chi-Hoon Kim</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pusan National University Yangsan Hospital</name>
      <address>
        <city>Yangsan</city>
        <state>Gyeongsangnamdo</state>
        <zip>626-770</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>June-Hong Kim, MD, Ph D</last_name>
      <phone>82-55-360-1548</phone>
      <email>junehongk@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Minku Chon, MD, PhD</last_name>
      <phone>82-55-360-1458</phone>
      <email>chonmingu@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Yonghyun Park, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Minku Chon, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>June-Hong Kim, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kiwon Hwang, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sanghyun Lee, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeongsu Kim, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Suyong Lee, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hyunggon Je, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kiseok Choo, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chungnam National University Hospital (CNU Hospital)</name>
      <address>
        <city>Daejeon</city>
        <state>Jung-gu</state>
        <zip>35015</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jae-Hyeong Park, MD, PhD</last_name>
      <phone>+82-42-280-7795</phone>
    </contact>
    <investigator>
      <last_name>Jae-Hyeong Park</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yeungnam University Hospital</name>
      <address>
        <city>Daegu</city>
        <state>Nam-gu</state>
        <zip>42415</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Woong Kim</last_name>
      <phone>+82-53-620-3148</phone>
    </contact>
    <investigator>
      <last_name>Woong Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jung-Hee Lee</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ulsan Hospital</name>
      <address>
        <city>Ulsan</city>
        <state>Nam-gu</state>
        <zip>44686</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eun-Seok Shin</last_name>
      <phone>+82-52-259-5000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Songpa-gu</state>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Seung-whan Lee, MD, PhD</last_name>
      <phone>+82-2-3010-3170</phone>
    </contact>
    <investigator>
      <last_name>Min-Soo Cho, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gi-Byeong Nam, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Shin ES, Chon MK, Jun EJ, Park YH, Lee SH, Kim JS, Shin DH, Lee SY, Cho MS, Lee SW, Reinthaler M, Park JW, Nam GB, Lederman RJ, Won Y, Kim JH. Septal Reduction Using Transvenous Intramyocardial Cerclage Radiofrequency Ablation: Preclinical Feasibility. JACC Basic Transl Sci. 2020 Sep 30;5(10):988-998. doi: 10.1016/j.jacbts.2020.08.006. eCollection 2020 Oct.</citation>
    <PMID>33145462</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>February 17, 2021</study_first_submitted>
  <study_first_submitted_qc>February 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 25, 2021</study_first_posted>
  <last_update_submitted>April 22, 2021</last_update_submitted>
  <last_update_submitted_qc>April 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Seung-Whan Lee,MD,PhD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Transcatheter RF ablation</keyword>
  <keyword>Intraseptal ablation</keyword>
  <keyword>HOCM</keyword>
  <keyword>TauPnu</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Cardiomyopathy, Hypertrophic</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

